Akebia Therapeutics (AKBA) EBITDA Margin (2017 - 2026)

Akebia Therapeutics (AKBA) has 10 years of EBITDA Margin data on file, last reported at 16.91% in Q1 2026.

• EBITDA Margin for Q1 2026 came in at 16.91%, down 2757.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 8.83% (up 1568.0% YoY), and the FY2025 annual result was 2.26%, up 4107.0% from the prior year.
• EBITDA Margin advanced to 16.91% in Q1 2026 per AKBA's latest filing, from 21.25% in the prior quarter.
• Over five years, EBITDA Margin peaked at 68.0% in Q2 2022 and troughed at 153.51% in Q1 2022.
• A 5-year average of 31.26% and a median of 19.82% in 2023 frame the typical range for EBITDA Margin.
• The sharpest annual moves came in 2022 and 2023: EBITDA Margin soared 22494 bps in 2022, then plunged 8781 bps in 2023.
• A 5-year view of EBITDA Margin shows it stood at 10.88% in 2022, then surged by 110 bps to 1.09% in 2023, then tumbled by 4589 bps to 49.04% in 2024, then jumped by 57 bps to 21.25% in 2025, then increased by 20 bps to 16.91% in 2026.
• Business Quant data shows AKBA's EBITDA Margin at 16.91% in Q1 2026, 21.25% in Q4 2025, and 0.92% in Q3 2025.